Mucormycosis Market To Witness Increase In Revenues By 2028

 The report “Global Mucormycosis Market  2028” from PMR Market Research includes data and information about market structure and size. The purpose of this research is to give market knowledge and strategic insights to assist in decision making, making informed investment decisions, and identifying potential growth opportunities.

The global mucormycosis market size is expected to reach USD 616.1 million by 2028 according to a new study by Polaris Market Research

The research report adopts primary and secondary research approaches, resulting in a precise and accurate insight into the Mucormycosis industry. To examine the segments and provide a fair assessment of their influence on the worldwide market, analysts utilized a top-down and bottom-up strategy. The study begins with a market overview, which includes a brief description of the industry's current state as well as the major segments. It also lists the leading players in the global market.

Download Sample Copy :  https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample

A Porter's five forces analysis and SWOT analysis are included in the research study on the global Mucormycosis market, which empower to determine the market's accurate trajectory. Such effective market analysis tools helps to identify market’s major drivers, restraints, risks, and market opportunities. In addition to this, the research report also features statistics for global market as well as different regional markets.

Market Segmentation

The report features in-depth segmentation and sub-segmentation of the target market. The executive summary of the Mucormycosis market research provides a quick overview of the market. It discusses the key sectors and companies projected to shape the market in the coming years. The executive summary provides a non-biased view of the market. It describes how the market's demand and supply will be affected by shifting demographics. It goes over the regulatory adjustments that are expected to change people's buying behavior.

Exclusive Discount Offer on this Research Report : https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-discount-pricing

COVID-19 Pandemic Impact Analysis

This Mucormycosis market study discusses the impact of the COVID-19 pandemic on macro and micro aspects of business, hurdles encountered by each sector, and continuous efforts to turn this crisis into an opportunity. The research report also discusses government policies for recovering the economy in detail, in order to assist businesses in expanding or entering new markets, as well as introducing new products and services.

Competitive Analysis

This section of the research study focuses on the market's leading players and competitive landscape. The Mucormycosis market study provides a list of strategic efforts undertaken by companies in recent years, as well as those anticipated in the near future. The financial prospects of these companies, their research and development activities, and their expansion plans for the near future have all been noted by researchers. The global market research report is a serious endeavor to provide interested readers with a thorough view of the market.

Market participants such as : Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences and Pfizer Inc.

Key Reason to buy this Mucormycosis Market Research Report

• It provides analytical data along with strategic planning approaches to help businesses make informed decisions.

• The market's dynamics, such as drivers, restraints, trends, and opportunities, are examined by researchers.

 

• It provides a wealth of information on current events that will have an impact on the market's overall performance.

 

• It includes regional analysis of the global market as well as corporate profiles of various stakeholders.

 

Read  More :

https://www.prnewswire.com/news-releases/womens-health-app-market-size-is-projected-to-reach-9-42-billion-by-2028--cagr-19-1--polaris-market-research-301437803.html

https://www.prnewswire.com/news-releases/supply-chain-analytics-market-is-projected-to-reach-15-61-billion-by-2028--cagr-17-5--pmr-301438851.html

https://www.prnewswire.com/news-releases/medical-engineered-materials-market-size-worth-44-62-billion-by-2028--cagr-12-9-pmr-301440002.html

 

 

 

Mucormycosis Market Will Witness Pronounced Growth During The Forecast Period

 Mucormycosis Industry: Global A Latest Research Report to Share Market Insights and Dynamics

The global mucormycosis market size is expected to reach USD 616.1 million by 2028 according to a new study by Polaris Market Research. The report “Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period. Organ and bone marrow transplantation along with increasing immune-competent patients due to the conditions like HIV will also boost the growth of the global market.

 

COVID-19 has significantly impacted the globe with over 150 million cases detected worldwide. Brazil is the third-worst affected country with more than 15 million cases and India which is clocking more cases than any other country, in May 2021, and has detected more than 20 million cases from the beginning of the pandemic. Mucormycosis cases are increased in the COVID-19 patients who have undergone treatment.

 

Get Sample Copy :  https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample

 

Steroid drugs are typically used to manage the disease condition in these patients and even though the drugs are effective in treating corona it will lead to weak immune system and blood sugar level and the patients who taken steroid medication are prone to developing mucormycosis.

 

In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment. Before the pandemic, mucormycosis was very rare and the emergence of COVID-19 is expected to give a major boost to the growth of the global market.

  

Every year nearly 1.8 million hematological cancers are diagnosed across the globe and bone marrow transplantation is a treatment procedure to treat these conditions. The improved technology has resulted in the increased organ transplantation in the market.

 

In the U.S. market alone, nearly, 37,000 organ transplant procedures were conducted, in 2018. Most of the patients who underwent transplant take immunosuppressive drugs which will put them at the risk of developing mucormycosis.

 

Mucormycosis is a deadly fungal disease caused by species such as Rhizopus, Mucor, Saksenaea, Apophysomyces, Lichtheimia, Cunninghamella, Rhizomucor, and others. The mortality rate of mucormycosis ranges from 17 to 66% in patients and the patients who overcome mucormycosis will suffer from blindness and organ dysfunction.

 

Get Discount Offer : https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-discount-pricing

 

Computed tomography (CT), Magnetic resonance imaging (MRI), and tissue biopsy are mainly used in the diagnosis of fungal infection in the market. Amphotericin B therapy, surgery, and antifungal drugs are the main treatment methods to cure mucormycosis.

 

Many new drugs in the market are approved to treat mucormycosis due to the increasing number of fungal infections. For instance, in March 2021, Bharat Serums and Vaccines Limited received Indian regulatory approval (DGCI) for the use of Liposomal Amphotericin B or LAmB for the treatment of mucormycosis.

 

Market Participants such as Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences, and Pfizer Inc. are some of the key players operating in the global market.

 

Polaris Market Research has segmented the mucormycosis market report on the basis of diagnosis, treatment, end-use, and region:

 

Mucormycosis, Diagnosis Outlook (Revenue – USD Million, 2016 – 2028)

• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Tissue Biopsy
• Others

Mucormycosis, Treatment Outlook (Revenue – USD Million, 2016 – 2028)

• Surgery
• Antifungal Drugs
• Posaconazole
• Isavuconazole
• Voriconazole
• Fluconazole
• Flucytosine
• Others
• Amphotericin B Therapy
• Others

Mucormycosis, End use Outlook (Revenue – USD Million, 2016 – 2028)

• Hospitals & Clinics
• Medical Institutes
• Research Organization
• Others

 

Mucormycosis Market By Size, Trends, Dynamic Innovation And Key Players

 The global mucormycosis market size is expected to reach USD 616.1 million by 2028 according to a new study by Polaris Market Research. The report “Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period. Organ and bone marrow transplantation along with increasing immune-competent patients due to the conditions like HIV will also boost the growth of the global market.

 

COVID-19 has significantly impacted the globe with over 150 million cases detected worldwide. Brazil is the third-worst affected country with more than 15 million cases and India which is clocking more cases than any other country, in May 2021, and has detected more than 20 million cases from the beginning of the pandemic. Mucormycosis cases are increased in the COVID-19 patients who have undergone treatment.

 

Get Sample Copy :  https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample

 

Steroid drugs are typically used to manage the disease condition in these patients and even though the drugs are effective in treating corona it will lead to weak immune system and blood sugar level and the patients who taken steroid medication are prone to developing mucormycosis.

 

In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment. Before the pandemic, mucormycosis was very rare and the emergence of COVID-19 is expected to give a major boost to the growth of the global market.

  

Every year nearly 1.8 million hematological cancers are diagnosed across the globe and bone marrow transplantation is a treatment procedure to treat these conditions. The improved technology has resulted in the increased organ transplantation in the market.

 

In the U.S. market alone, nearly, 37,000 organ transplant procedures were conducted, in 2018. Most of the patients who underwent transplant take immunosuppressive drugs which will put them at the risk of developing mucormycosis.

 

Mucormycosis is a deadly fungal disease caused by species such as Rhizopus, Mucor, Saksenaea, Apophysomyces, Lichtheimia, Cunninghamella, Rhizomucor, and others. The mortality rate of mucormycosis ranges from 17 to 66% in patients and the patients who overcome mucormycosis will suffer from blindness and organ dysfunction.

 

Get Discount Offer : https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-discount-pricing

 

Computed tomography (CT), Magnetic resonance imaging (MRI), and tissue biopsy are mainly used in the diagnosis of fungal infection in the market. Amphotericin B therapy, surgery, and antifungal drugs are the main treatment methods to cure mucormycosis.

 

Many new drugs in the market are approved to treat mucormycosis due to the increasing number of fungal infections. For instance, in March 2021, Bharat Serums and Vaccines Limited received Indian regulatory approval (DGCI) for the use of Liposomal Amphotericin B or LAmB for the treatment of mucormycosis.

 

Market Participants such as Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences, and Pfizer Inc. are some of the key players operating in the global market.

 

Polaris Market Research has segmented the mucormycosis market report on the basis of diagnosis, treatment, end-use, and region:

 

Mucormycosis, Diagnosis Outlook (Revenue – USD Million, 2016 – 2028)

• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Tissue Biopsy
• Others

Mucormycosis, Treatment Outlook (Revenue – USD Million, 2016 – 2028)

• Surgery
• Antifungal Drugs
• Posaconazole
• Isavuconazole
• Voriconazole
• Fluconazole
• Flucytosine
• Others
• Amphotericin B Therapy
• Others

Mucormycosis, End use Outlook (Revenue – USD Million, 2016 – 2028)

• Hospitals & Clinics
• Medical Institutes
• Research Organization
• Others

 

Mucormycosis Market Size, Recent Advancement & Scope Top Trends

 The global mucormycosis market size is expected to reach USD 616.1 million by 2028 according to a new study by Polaris Market Research. The report “Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period. Organ and bone marrow transplantation along with increasing immune-competent patients due to the conditions like HIV will also boost the growth of the global market.

 

COVID-19 has significantly impacted the globe with over 150 million cases detected worldwide. Brazil is the third-worst affected country with more than 15 million cases and India which is clocking more cases than any other country, in May 2021, and has detected more than 20 million cases from the beginning of the pandemic. Mucormycosis cases are increased in the COVID-19 patients who have undergone treatment.

 

Get Sample Copy :  https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample

 

Steroid drugs are typically used to manage the disease condition in these patients and even though the drugs are effective in treating corona it will lead to weak immune system and blood sugar level and the patients who taken steroid medication are prone to developing mucormycosis.

 

In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment. Before the pandemic, mucormycosis was very rare and the emergence of COVID-19 is expected to give a major boost to the growth of the global market.

  

Every year nearly 1.8 million hematological cancers are diagnosed across the globe and bone marrow transplantation is a treatment procedure to treat these conditions. The improved technology has resulted in the increased organ transplantation in the market.

 

In the U.S. market alone, nearly, 37,000 organ transplant procedures were conducted, in 2018. Most of the patients who underwent transplant take immunosuppressive drugs which will put them at the risk of developing mucormycosis.

 

Mucormycosis is a deadly fungal disease caused by species such as Rhizopus, Mucor, Saksenaea, Apophysomyces, Lichtheimia, Cunninghamella, Rhizomucor, and others. The mortality rate of mucormycosis ranges from 17 to 66% in patients and the patients who overcome mucormycosis will suffer from blindness and organ dysfunction.

 

Get Discount Offer : https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-discount-pricing

 

Computed tomography (CT), Magnetic resonance imaging (MRI), and tissue biopsy are mainly used in the diagnosis of fungal infection in the market. Amphotericin B therapy, surgery, and antifungal drugs are the main treatment methods to cure mucormycosis.

 

Many new drugs in the market are approved to treat mucormycosis due to the increasing number of fungal infections. For instance, in March 2021, Bharat Serums and Vaccines Limited received Indian regulatory approval (DGCI) for the use of Liposomal Amphotericin B or LAmB for the treatment of mucormycosis.

 

Market Participants such as Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences, and Pfizer Inc. are some of the key players operating in the global market.

 

Polaris Market Research has segmented the mucormycosis market report on the basis of diagnosis, treatment, end-use, and region:

 

Mucormycosis, Diagnosis Outlook (Revenue – USD Million, 2016 – 2028)

• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Tissue Biopsy
• Others

Mucormycosis, Treatment Outlook (Revenue – USD Million, 2016 – 2028)

• Surgery
• Antifungal Drugs
• Posaconazole
• Isavuconazole
• Voriconazole
• Fluconazole
• Flucytosine
• Others
• Amphotericin B Therapy
• Others

Mucormycosis, End use Outlook (Revenue – USD Million, 2016 – 2028)

• Hospitals & Clinics
• Medical Institutes
• Research Organization
• Others

 

Mucormycosis Market Global Forthcoming Developments, Business Opportunities & Future Investments

 The global mucormycosis market size is expected to reach USD 616.1 million by 2028 according to a new study by Polaris Market Research. The report “Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period. Organ and bone marrow transplantation along with increasing immune-competent patients due to the conditions like HIV will also boost the growth of the global market.

 

COVID-19 has significantly impacted the globe with over 150 million cases detected worldwide. Brazil is the third-worst affected country with more than 15 million cases and India which is clocking more cases than any other country, in May 2021, and has detected more than 20 million cases from the beginning of the pandemic. Mucormycosis cases are increased in the COVID-19 patients who have undergone treatment.

 

Get Sample Copy :  https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample

 

Steroid drugs are typically used to manage the disease condition in these patients and even though the drugs are effective in treating corona it will lead to weak immune system and blood sugar level and the patients who taken steroid medication are prone to developing mucormycosis.

 

In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment. Before the pandemic, mucormycosis was very rare and the emergence of COVID-19 is expected to give a major boost to the growth of the global market.

  

Every year nearly 1.8 million hematological cancers are diagnosed across the globe and bone marrow transplantation is a treatment procedure to treat these conditions. The improved technology has resulted in the increased organ transplantation in the market.

 

In the U.S. market alone, nearly, 37,000 organ transplant procedures were conducted, in 2018. Most of the patients who underwent transplant take immunosuppressive drugs which will put them at the risk of developing mucormycosis.

 

Mucormycosis is a deadly fungal disease caused by species such as Rhizopus, Mucor, Saksenaea, Apophysomyces, Lichtheimia, Cunninghamella, Rhizomucor, and others. The mortality rate of mucormycosis ranges from 17 to 66% in patients and the patients who overcome mucormycosis will suffer from blindness and organ dysfunction.

 

Get Discount Offer : https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-discount-pricing

 

Computed tomography (CT), Magnetic resonance imaging (MRI), and tissue biopsy are mainly used in the diagnosis of fungal infection in the market. Amphotericin B therapy, surgery, and antifungal drugs are the main treatment methods to cure mucormycosis.

 

Many new drugs in the market are approved to treat mucormycosis due to the increasing number of fungal infections. For instance, in March 2021, Bharat Serums and Vaccines Limited received Indian regulatory approval (DGCI) for the use of Liposomal Amphotericin B or LAmB for the treatment of mucormycosis.

 

Market Participants such as Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences, and Pfizer Inc. are some of the key players operating in the global market.

 

Polaris Market Research has segmented the mucormycosis market report on the basis of diagnosis, treatment, end-use, and region:

 

Mucormycosis, Diagnosis Outlook (Revenue – USD Million, 2016 – 2028)

• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Tissue Biopsy
• Others

Mucormycosis, Treatment Outlook (Revenue – USD Million, 2016 – 2028)

• Surgery
• Antifungal Drugs
• Posaconazole
• Isavuconazole
• Voriconazole
• Fluconazole
• Flucytosine
• Others
• Amphotericin B Therapy
• Others

Mucormycosis, End use Outlook (Revenue – USD Million, 2016 – 2028)

• Hospitals & Clinics
• Medical Institutes
• Research Organization
• Others

 

Mucormycosis Market Overview, Trends Forecast Analysis By Top Manufactures

 The global mucormycosis market size is expected to reach USD 616.1 million by 2028 according to a new study by Polaris Market Research. The report “Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period. Organ and bone marrow transplantation along with increasing immune-competent patients due to the conditions like HIV will also boost the growth of the global market.

 

COVID-19 has significantly impacted the globe with over 150 million cases detected worldwide. Brazil is the third-worst affected country with more than 15 million cases and India which is clocking more cases than any other country, in May 2021, and has detected more than 20 million cases from the beginning of the pandemic. Mucormycosis cases are increased in the COVID-19 patients who have undergone treatment.

 

Get Sample Copy :  https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample

 

Steroid drugs are typically used to manage the disease condition in these patients and even though the drugs are effective in treating corona it will lead to weak immune system and blood sugar level and the patients who taken steroid medication are prone to developing mucormycosis.

 

In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment. Before the pandemic, mucormycosis was very rare and the emergence of COVID-19 is expected to give a major boost to the growth of the global market.

  

Every year nearly 1.8 million hematological cancers are diagnosed across the globe and bone marrow transplantation is a treatment procedure to treat these conditions. The improved technology has resulted in the increased organ transplantation in the market.

 

In the U.S. market alone, nearly, 37,000 organ transplant procedures were conducted, in 2018. Most of the patients who underwent transplant take immunosuppressive drugs which will put them at the risk of developing mucormycosis.

 

Mucormycosis is a deadly fungal disease caused by species such as Rhizopus, Mucor, Saksenaea, Apophysomyces, Lichtheimia, Cunninghamella, Rhizomucor, and others. The mortality rate of mucormycosis ranges from 17 to 66% in patients and the patients who overcome mucormycosis will suffer from blindness and organ dysfunction.

 

Get Discount Offer : https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-discount-pricing

 

Computed tomography (CT), Magnetic resonance imaging (MRI), and tissue biopsy are mainly used in the diagnosis of fungal infection in the market. Amphotericin B therapy, surgery, and antifungal drugs are the main treatment methods to cure mucormycosis.

 

Many new drugs in the market are approved to treat mucormycosis due to the increasing number of fungal infections. For instance, in March 2021, Bharat Serums and Vaccines Limited received Indian regulatory approval (DGCI) for the use of Liposomal Amphotericin B or LAmB for the treatment of mucormycosis.

 

Market Participants such as Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences, and Pfizer Inc. are some of the key players operating in the global market.

 

Polaris Market Research has segmented the mucormycosis market report on the basis of diagnosis, treatment, end-use, and region:

 

Mucormycosis, Diagnosis Outlook (Revenue – USD Million, 2016 – 2028)

• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Tissue Biopsy
• Others

Mucormycosis, Treatment Outlook (Revenue – USD Million, 2016 – 2028)

• Surgery
• Antifungal Drugs
• Posaconazole
• Isavuconazole
• Voriconazole
• Fluconazole
• Flucytosine
• Others
• Amphotericin B Therapy
• Others

Mucormycosis, End use Outlook (Revenue – USD Million, 2016 – 2028)

• Hospitals & Clinics
• Medical Institutes
• Research Organization
• Others

 

Mucormycosis Market Quantitative Assessment by Industry Analysis across the Value Chain

 Mucormycosis | 2021 Scope of Current and Future Industry 

The global mucormycosis market size is expected to reach USD 616.1 million by 2028 according to a new study by Polaris Market Research. The report “Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period. Organ and bone marrow transplantation along with increasing immune-competent patients due to the conditions like HIV will also boost the growth of the global market.

 

COVID-19 has significantly impacted the globe with over 150 million cases detected worldwide. Brazil is the third-worst affected country with more than 15 million cases and India which is clocking more cases than any other country, in May 2021, and has detected more than 20 million cases from the beginning of the pandemic. Mucormycosis cases are increased in the COVID-19 patients who have undergone treatment.

 

Get Sample Copy :  https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample

 

Steroid drugs are typically used to manage the disease condition in these patients and even though the drugs are effective in treating corona it will lead to weak immune system and blood sugar level and the patients who taken steroid medication are prone to developing mucormycosis.

 

In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment. Before the pandemic, mucormycosis was very rare and the emergence of COVID-19 is expected to give a major boost to the growth of the global market.

  

Every year nearly 1.8 million hematological cancers are diagnosed across the globe and bone marrow transplantation is a treatment procedure to treat these conditions. The improved technology has resulted in the increased organ transplantation in the market.

 

In the U.S. market alone, nearly, 37,000 organ transplant procedures were conducted, in 2018. Most of the patients who underwent transplant take immunosuppressive drugs which will put them at the risk of developing mucormycosis.

 

Mucormycosis is a deadly fungal disease caused by species such as Rhizopus, Mucor, Saksenaea, Apophysomyces, Lichtheimia, Cunninghamella, Rhizomucor, and others. The mortality rate of mucormycosis ranges from 17 to 66% in patients and the patients who overcome mucormycosis will suffer from blindness and organ dysfunction.

 

Get Discount Offer : https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-discount-pricing

 

Computed tomography (CT), Magnetic resonance imaging (MRI), and tissue biopsy are mainly used in the diagnosis of fungal infection in the market. Amphotericin B therapy, surgery, and antifungal drugs are the main treatment methods to cure mucormycosis.

 

Many new drugs in the market are approved to treat mucormycosis due to the increasing number of fungal infections. For instance, in March 2021, Bharat Serums and Vaccines Limited received Indian regulatory approval (DGCI) for the use of Liposomal Amphotericin B or LAmB for the treatment of mucormycosis.

 

Market Participants such as Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences, and Pfizer Inc. are some of the key players operating in the global market.

 

Polaris Market Research has segmented the mucormycosis market report on the basis of diagnosis, treatment, end-use, and region:

 

Mucormycosis, Diagnosis Outlook (Revenue – USD Million, 2016 – 2028)

• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Tissue Biopsy
• Others

Mucormycosis, Treatment Outlook (Revenue – USD Million, 2016 – 2028)

• Surgery
• Antifungal Drugs
• Posaconazole
• Isavuconazole
• Voriconazole
• Fluconazole
• Flucytosine
• Others
• Amphotericin B Therapy
• Others

Mucormycosis, End use Outlook (Revenue – USD Million, 2016 – 2028)

• Hospitals & Clinics
• Medical Institutes
• Research Organization
• Others

 

Mucormycosis Market SWOT Analysis, Growth Rate of Top Manufacturers Profiles

 The global mucormycosis market size is expected to reach USD 616.1 million by 2028 according to a new study by Polaris Market Research. The report “Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

 

The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period. Organ and bone marrow transplantation along with increasing immune-competent patients due to the conditions like HIV will also boost the growth of the global market.

 

COVID-19 has significantly impacted the globe with over 150 million cases detected worldwide. Brazil is the third-worst affected country with more than 15 million cases and India which is clocking more cases than any other country, in May 2021, and has detected more than 20 million cases from the beginning of the pandemic. Mucormycosis cases are increased in the COVID-19 patients who have undergone treatment.

 

Get Sample Copy :  https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-sample

 

Steroid drugs are typically used to manage the disease condition in these patients and even though the drugs are effective in treating corona it will lead to weak immune system and blood sugar level and the patients who taken steroid medication are prone to developing mucormycosis.

 

In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment. Before the pandemic, mucormycosis was very rare and the emergence of COVID-19 is expected to give a major boost to the growth of the global market.

  

Every year nearly 1.8 million hematological cancers are diagnosed across the globe and bone marrow transplantation is a treatment procedure to treat these conditions. The improved technology has resulted in the increased organ transplantation in the market.

 

In the U.S. market alone, nearly, 37,000 organ transplant procedures were conducted, in 2018. Most of the patients who underwent transplant take immunosuppressive drugs which will put them at the risk of developing mucormycosis.

 

Mucormycosis is a deadly fungal disease caused by species such as Rhizopus, Mucor, Saksenaea, Apophysomyces, Lichtheimia, Cunninghamella, Rhizomucor, and others. The mortality rate of mucormycosis ranges from 17 to 66% in patients and the patients who overcome mucormycosis will suffer from blindness and organ dysfunction.

 

Get Discount Offer : https://www.polarismarketresearch.com/industry-analysis/mucormycosis-market/request-for-discount-pricing

 

Computed tomography (CT), Magnetic resonance imaging (MRI), and tissue biopsy are mainly used in the diagnosis of fungal infection in the market. Amphotericin B therapy, surgery, and antifungal drugs are the main treatment methods to cure mucormycosis.

 

Many new drugs in the market are approved to treat mucormycosis due to the increasing number of fungal infections. For instance, in March 2021, Bharat Serums and Vaccines Limited received Indian regulatory approval (DGCI) for the use of Liposomal Amphotericin B or LAmB for the treatment of mucormycosis.

 

Market Participants such as Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences, and Pfizer Inc. are some of the key players operating in the global market.

 

Polaris Market Research has segmented the mucormycosis market report on the basis of diagnosis, treatment, end-use, and region:

 

Mucormycosis, Diagnosis Outlook (Revenue – USD Million, 2016 – 2028)

• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Tissue Biopsy
• Others

Mucormycosis, Treatment Outlook (Revenue – USD Million, 2016 – 2028)

• Surgery
• Antifungal Drugs
• Posaconazole
• Isavuconazole
• Voriconazole
• Fluconazole
• Flucytosine
• Others
• Amphotericin B Therapy
• Others

Mucormycosis, End use Outlook (Revenue – USD Million, 2016 – 2028)

• Hospitals & Clinics
• Medical Institutes
• Research Organization
• Others